Brooks Laboratories Limited - pharma in Nalagarh, Himachal Pradesh, India. FY 2026 financials & compliance.
CIN L24232HP2002PLC000267 Incorporated 23 January 2002 ROC Himachal Pradesh HQ Nalagarh, Himachal Pradesh, India
Active Listed - NSE: BROOKS · BSE: 533543 Public Limited Company pharma MSME · Medium
Market Cap
₹197 Cr
BROOKS · NSE
Share Price
₹67.30
+0.51% today
Revenue
₹85.74 Cr
FY 2025-26 · +3.9% YoY
EBITDA
₹7.07 Cr
Margin 8.2%
Net Profit
₹24.30 Cr
FY 2025-26 · +343.2% YoY
P/E (TTM)
59.5x
P/B 1.1x
Authorised capital
₹30 Cr
Registered with MCA
Paid-up capital
₹29.46 Cr
Issued & subscribed

About Brooks Laboratories Limited

Data last updated:

Brooks Laboratories Limited is a public limited company based in Nalagarh, Himachal Pradesh, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 23 January 2002 and has been in existence for over 24 years.

The company is registered with the Registrar of Companies (ROC), Himachal Pradesh, under CIN L24232HP2002PLC000267. Its GSTIN is 02AACCB5316P1ZR (Himachal Pradesh). The company holds 7 GST registrations, of which 5 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 533543 and NSE: BROOKS.

The company has an authorised share capital of ₹30 Cr and a paid-up capital of ₹29.46 Cr. It is led by directors including Jitendrapratap Rambahadur Singh (Whole-Time Director) and Bhushan Singh Rana (Whole-Time Director).

Its last annual general meeting (AGM) was held on 03 September 2026, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Village Kishanpura Nalagarh Road Baddi, Himachal Pradesh, India – 174101.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹85.74 Cr, a growth of 3.9% compared to the previous year. For the same year it recorded a net profit of ₹24.3 Cr (net margin 28.3%) and EBITDA of ₹7.07 Cr (EBITDA margin 8.2%). The net worth stands at ₹122.66 Cr (up 25% YoY). Total assets are valued at ₹132.78 Cr (up 24% YoY).

The company has about 304 employees on its provident fund (EPFO) records.

The company is associated with 1 brand: Brooks Laboratories. As per MCA filings, the company has open charges of ₹74.08 Cr and satisfied charges of ₹179.36 Cr on record. Court records list 22 cases involving the company, including 10 filed by the company and 12 filed against it; 4 cases are pending. The company has 58 deals on record (55 market trades, 1 funding round, 1 rights issue), with disclosed funding of ₹11.58 Cr; the latest was in May 2026. The company has 12 MSME Form 1 returns on record between 2019 and 2024, listing 699 overdue payments to 238 micro and small suppliers.

Brooks Laboratories Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-HP-11-0000560). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website brookslabs.net.

Company details

CIN L24232HP2002PLC000267
Registration Number 000267
Incorporation Date 23 January 2002
ROC Himachal Pradesh
Listing Status Listed - Listed on NSE (BROOKS); Listed on BSE (533543)
Company Status Active
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-HP-11-0000560

CIN history

Brooks Laboratories has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24232HP2002PLC000267, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24232HP2002PLC000267Current
U24232PB2002PLC024910Previous
L24232PB2002PLC024910Previous

Recognitions & Rankings of Brooks Laboratories

MSME (Udyam registered) Ministry of MSME
Category
Medium (2023-24)
Udyam number
UDYAM-HP-11-0000560

Contact details

Brooks Laboratories Limited's registered office is in Nalagarh, Himachal Pradesh. Its website is brookslabs.net. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Social Media
  • Registered Address
    Village Kishanpura Nalagarh Road Baddi, Himachal Pradesh, India – 174101
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Brooks Laboratories Limited, buy the company report.

Comprehensive company report
Brooks Laboratories Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Brooks Laboratories operates one associated brand: Brooks Laboratories. Each brand links to its own profile.

BrandDescriptionWebsite
Manufacturer of pharmaceutical injectables, tablets, and oral suspensionsbrookslabs.net

Business activity

The main business activity of Brooks Laboratories is manufacturing. In detail, this covers manufacture of basic pharmaceutical products and pharmaceutical preparations.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturing21Manufacture of basic pharmaceutical products and pharmaceutical preparations

To see the full business activity and turnover split of Brooks Laboratories Limited, buy the company report.

Financials of Brooks Laboratories Limited

FY 2025-26 filings available

Brooks Laboratories Limited reported revenue of ₹85.74 Cr (up 3.9% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹85.74 Cr
+3.9% YoY
EBITDA
₹7.07 Cr
+187.9% YoY
Profit After Tax
₹24.30 Cr
+343.2% YoY
Net Worth
₹123 Cr
+25.0% YoY
Total Assets
₹133 Cr
+24.0% YoY
Total Debt
₹8.52 Cr
+12.4% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Income statement
Revenue85.7482.5679.4963.2091.1877.25
Revenue growth+3.9%+3.9%+25.8%-30.7%+18.0%-
EBITDA7.07(8.04)(17.86)(29.72)(14.27)0.53
EBITDA margin+8.3%-9.7%-22.5%-47.0%-15.7%+0.7%
Profit before tax24.59(9.79)(19.55)(38.36)(23.92)(8.97)
Net profit24.30(9.99)(19.59)(21.25)(11.44)(19.31)
Net profit margin+28.3%-12.1%-24.6%-33.6%-12.6%-25.0%
EPS (₹)8.35(3.38)(7.46)(8.46)(4.57)(7.84)
Balance sheet
Total assets13310772.6882.49162112
Net worth12398.1165.5973.9587.4979.15
Total debt8.527.585.646.5125.2631.38
Cash & bank7.551.250.691.083.811.70
Net working capital22.0117.2413.290.4927.430.69
Cash flow
Cash from operations9.292.63(9.80)(14.49)(37.44)4.46
Cash from investing(2.92)(45.14)0.180.49(24.91)(5.13)
Cash from financing0.1742.439.7211.4164.071.16
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue19.2522.9620.2116.5723.4525.5123.3220.52
Revenue growth (YoY)-17.9%-10.0%-13.3%-19.3%+12.8%+42.3%--
Other income75.680.181.355.326.137.150.620.03
EBITDA(2.06)(1.34)0.680.742.523.12(1.25)(1.49)
EBITDA margin-10.7%-5.8%+3.4%+4.5%+10.7%+12.2%-5.4%-7.3%
Depreciation0.450.420.410.390.390.390.390.38
Interest0.250.210.090.160.280.300.260.28
Profit before tax72.92(1.79)1.535.517.989.58(1.28)(2.12)
Tax5.320.000.000.000.000.000.180.00
Net profit67.60(1.79)1.535.517.989.58(1.46)(2.12)
EPS (₹)22.95(0.61)0.521.872.713.25(0.54)(0.82)
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue85.7482.5679.4955.5476.9777.2769.69
Revenue growth+3.9%+3.9%+43.1%-27.8%-0.4%+10.9%-
EBITDA7.074.983.26(5.81)1.880.94(3.92)
EBITDA margin+8.3%+6.0%+4.1%-10.5%+2.4%+1.2%-5.6%
Profit before tax5.813.231.57(8.18)0.67(8.44)(13.51)
Net profit5.523.031.53(8.19)0.41(15.53)(23.19)
Net profit margin+6.4%+3.7%+1.9%-14.8%+0.5%-20.1%-33.3%
EPS (₹)1.971.040.58(3.31)0.27(6.31)(9.87)
Balance sheet
Total assets13112476.6365.3173.1174.37128
Net worth12111569.5356.7865.0064.2198.41
Total debt8.527.585.646.515.978.4027.64
Cash & bank7.551.250.691.081.080.881.53
Net working capital22.0117.2413.290.496.696.717.82
Cash flow
Cash from operations9.292.63(9.80)0.553.12(0.90)(9.39)
Cash from investing(2.92)(45.14)0.18(0.40)1.12(0.74)(2.33)
Cash from financing0.1742.439.72(0.21)(4.22)1.319.61
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue19.2522.9620.2116.5723.4525.5123.3220.52
Revenue growth (YoY)-17.9%-10.0%-13.3%-19.3%+12.8%+42.3%--
Other income75.680.180.440.130.390.220.620.03
Total expenses18.9321.1019.5315.8320.9322.3921.7418.94
EBITDA0.321.860.680.742.523.121.581.58
EBITDA margin+1.7%+8.1%+3.4%+4.5%+10.7%+12.2%+6.8%+7.7%
Depreciation0.450.420.410.390.390.390.390.38
Interest0.250.210.090.160.280.300.260.28
Profit before tax75.301.410.620.322.242.651.550.95
Tax5.320.000.000.000.000.000.180.00

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 19 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue19.2522.9620.2116.5723.4525.5123.3220.52
Revenue growth (YoY)-17.9%-10.0%-13.3%-19.3%+12.8%+42.3%--
Other income75.680.181.355.326.137.150.620.03
EBITDA(2.06)(1.34)0.680.742.523.12(1.25)(1.49)
EBITDA margin-10.7%-5.8%+3.4%+4.5%+10.7%+12.2%-5.4%-7.3%
Depreciation0.450.420.410.390.390.390.390.38
Interest0.250.210.090.160.280.300.260.28
Profit before tax72.92(1.79)1.535.517.989.58(1.28)(2.12)
Tax5.320.000.000.000.000.000.180.00
Net profit67.60(1.79)1.535.517.989.58(1.46)(2.12)
EPS (₹)22.95(0.61)0.521.872.713.25(0.54)(0.82)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Revenue85.7482.5679.4963.2091.1877.25
Revenue growth+3.9%+3.9%+25.8%-30.7%+18.0%-
Other income19.950.880.920.570.800.74
Total expenses78.6790.6097.3592.9210576.72
Employee cost14.6212.4510.0916.0016.8512.04
EBITDA7.07(8.04)(17.86)(29.72)(14.27)0.53
EBITDA margin+8.3%-9.7%-22.5%-47.0%-15.7%+0.7%
Depreciation1.591.601.777.037.357.14
Interest0.841.030.842.183.103.10
Profit before tax24.59(9.79)(19.55)(38.36)(23.92)(8.97)
Tax0.000.180.03(7.32)(4.59)10.38
Net profit24.30(9.99)(19.59)(21.25)(11.44)(19.31)
Net profit margin+28.3%-12.1%-24.6%-33.6%-12.6%-25.0%
EPS (₹)8.35(3.38)(7.46)(8.46)(4.57)(7.84)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Equity & liabilities
Share capital29.4629.4626.2524.7024.7024.70
Reserves & surplus93.2068.6539.3449.2562.7954.45
Shareholders' funds (net worth)12398.1165.5973.9587.4979.15
Minority interest0.000.000.000.0046.830.00
Secured loans7.286.065.045.6624.2131.38
Unsecured loans1.241.520.600.851.050.00
Total debt8.527.585.646.5125.2631.38
Total liabilities13310772.6882.49162112
Assets
Gross block26.0025.1523.2722.83143133
Net block14.5213.9813.6715.00110108
Capital work in progress1.190.000.000.0015.110.83
Investments92.3473.5542.9164.030.060.02
Inventories11.029.209.6111.3027.5223.60
Sundry debtors16.1119.9916.3212.7517.6613.70
Cash & bank balances7.551.250.691.083.811.70
Loans & advances2.733.434.432.4712.198.36
Total current assets37.4133.8731.0527.6061.1847.36
Total current liabilities15.4016.6317.7627.1133.7546.67
Net working capital22.0117.2413.290.4927.430.69
Total assets13310772.6882.49162112
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Opening cash0.040.130.022.610.880.40
Net cash from operating activities9.292.63(9.80)(14.49)(37.44)4.46
Net cash from investing activities(2.92)(45.14)0.180.49(24.91)(5.13)
Net cash from financing activities0.1742.439.7211.4164.071.16
Net change in cash6.54(0.08)0.10(2.58)1.720.49
Closing cash7.551.250.691.083.811.70
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Growth
Sales growth+3.9%+3.9%+25.8%-30.7%+18.0%-
EBITDA growth+187.9%+55.0%+39.9%-108.3%-2792.5%-
PBT growth+9998.0%+49.9%+49.0%-60.4%-166.7%+9997.0%
Net income growth+343.2%+49.0%+7.8%-85.8%+40.8%-
Revenue CAGR (3Y)+10.7%-3.3%+1.0%---
EBITDA CAGR (3Y)--17.4%----
Profitability & leverage
Net income margin+28.7%-12.1%-24.6%-49.1%-21.2%-25.1%
Return on capital employed-0.0%0.0%0.0%0.0%0.0%
Return on net worth-0.0%0.0%0.0%0.0%0.0%
Debt / equity-0.080.090.200.400.40
Long-term debt / equity-0.010.010.070.170.18
Interest cover15.33-10.68-4.28-5.93-14.34-46.90
Efficiency & per share
Fixed asset turnover-3.413.450.760.660.58
Inventory turnover-8.787.603.263.563.27
Debtors turnover-4.555.474.165.815.64
EPS (₹)8.35(3.38)(7.46)(8.46)(4.57)(7.84)
Dividend per share (₹)0.000.000.000.000.000.00
Book value per share (₹)41.6433.3024.9929.9435.4232.04
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue19.2522.9620.2116.5723.4525.5123.3220.52
Revenue growth (YoY)-17.9%-10.0%-13.3%-19.3%+12.8%+42.3%--
Other income75.680.180.440.130.390.220.620.03
Total expenses18.9321.1019.5315.8320.9322.3921.7418.94
EBITDA0.321.860.680.742.523.121.581.58
EBITDA margin+1.7%+8.1%+3.4%+4.5%+10.7%+12.2%+6.8%+7.7%
Depreciation0.450.420.410.390.390.390.390.38
Interest0.250.210.090.160.280.300.260.28
Profit before tax75.301.410.620.322.242.651.550.95
Tax5.320.000.000.000.000.000.180.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue85.7482.5679.4955.5476.9777.2769.69
Revenue growth+3.9%+3.9%+43.1%-27.8%-0.4%+10.9%-
Other income1.170.880.920.120.950.960.41
Total expenses78.6777.5876.2361.3575.0976.3373.61
Employee cost14.6212.4510.0910.6510.8812.0411.16
EBITDA7.074.983.26(5.81)1.880.94(3.92)
EBITDA margin+8.3%+6.0%+4.1%-10.5%+2.4%+1.2%-5.6%
Depreciation1.591.601.771.721.497.096.65
Interest0.841.030.840.770.673.253.35
Profit before tax5.813.231.57(8.18)0.67(8.44)(13.51)
Tax0.000.180.030.000.007.1510.86
Net profit5.523.031.53(8.19)0.41(15.53)(23.19)
Net profit margin+6.4%+3.7%+1.9%-14.8%+0.5%-20.1%-33.3%
EPS (₹)1.971.040.58(3.31)0.27(6.31)(9.87)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital29.4629.4626.2524.7024.7024.7024.70
Reserves & surplus91.3985.6143.2832.0840.3039.5173.71
Shareholders' funds (net worth)12111569.5356.7865.0064.2198.41
Secured loans7.286.065.045.664.928.4026.88
Unsecured loans1.241.520.600.851.050.000.76
Total debt8.527.585.646.515.978.4027.64
Total liabilities13112476.6365.3173.1174.37128
Assets
Gross block26.0025.1523.2722.8321.0719.64133
Net block14.5213.9813.6715.0015.1414.96113
Capital work in progress1.190.000.000.001.120.020.11
Investments90.5390.5246.8646.8546.8446.810.02
Inventories11.029.209.6111.3016.5912.3813.77
Sundry debtors16.1119.9916.3212.7515.039.5915.56
Cash & bank balances7.551.250.691.081.080.881.53
Loans & advances2.733.434.432.474.342.497.05
Total current assets37.4133.8731.0527.6037.0425.3437.91
Total current liabilities15.4016.6317.7627.1130.3518.6330.09
Net working capital22.0117.2413.290.496.696.717.82
Total assets13112476.6365.3173.1174.37128
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.040.130.020.080.060.402.50
Net cash from operating activities9.292.63(9.80)0.553.12(0.90)(9.39)
Net cash from investing activities(2.92)(45.14)0.18(0.40)1.12(0.74)(2.33)
Net cash from financing activities0.1742.439.72(0.21)(4.22)1.319.61
Net change in cash6.54(0.08)0.10(0.06)0.02(0.33)(2.10)
Closing cash7.551.250.691.081.080.881.53
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+3.9%+3.9%+43.1%-27.8%-0.4%+10.9%-
EBITDA growth+42.0%+52.8%+156.1%-409.0%+100.0%+124.0%-
PBT growth+79.9%+105.7%+9998.0%-+9998.0%+37.5%+9.6%
Net income growth+82.2%+98.0%+118.7%-2097.6%+102.6%+33.0%-
Revenue CAGR (3Y)+15.6%+2.4%+1.0%-7.3%+11.8%+11.5%+6.6%
EBITDA CAGR (3Y)-+38.4%+51.4%+14.0%---
Profitability & leverage
Net income margin+6.8%+3.7%+1.9%-14.7%+0.9%-20.2%-35.0%
Return on capital employed+4.3%+3.2%+2.7%0.0%+1.2%0.0%-7.7%
Return on net worth+4.0%+2.4%+1.9%0.0%+0.5%0.0%-24.0%
Debt / equity0.070.070.100.100.110.220.29
Long-term debt / equity0.010.010.010.010.020.080.13
Interest cover15.3330.4756.38-10.23171.79-52.85-31.69
Efficiency & per share
Fixed asset turnover3.353.413.452.533.781.020.53
Inventory turnover8.488.787.603.985.315.915.85
Debtors turnover4.754.555.474.006.256.145.17
EPS (₹)1.971.040.58(3.31)0.27(6.31)(9.87)
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)41.0239.0626.4922.9826.3125.9939.84

To see the full year-wise statements and ratios of Brooks Laboratories Limited, buy the company report.

Board of directors of Brooks Laboratories Limited

Brooks Laboratories has 6 current directors and 21 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Jitendrapratap Rambahadur SinghWhole-Time Director23 Nov 20223 Years 11 MonthsCurrent
Lalit MahajanDirector07 Aug 20242 Years 3 MonthsCurrent
Usha SinghDirector07 Aug 20242 Years 3 MonthsCurrent
Manav MahajanDirector28 Sep 20242 Years 1 MonthsCurrent
Bhushan Singh RanaWhole-Time Director23 Aug 20233 Years 2 MonthsCurrent
Durga Shankar MaityWhole-Time Director07 Jul 20233 Years 4 MonthsCurrent

Auditor

Brooks Laboratories Limited is audited by DMKH & Co. for the financial year 2025.

Auditor firmFinancial yearFirm registration number
DMKH & Co.FY 2025116886W

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 52.60%, foreign institutional investors hold 0.00%, domestic institutional investors hold 10.40% and retail and other public shareholders hold 37.00%.

Promoters: 52.60%DII (Domestic Institutional): 10.40%Retail & Others: 37.00%
Sep 2026
QUARTER
52.60% Promoters
10.40% DII (Domestic Institutional)
37.00% Retail & Others
Promoter holding - history
Now 52.60% · Sep 2026High 52.60% · Dec 2025Low 52.60% · Dec 2025
51%51.8%52.5%53.3%54%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 52.60%Mar 2026: 52.60%Jun 2026: 52.60%Sep 2026: 52.60%52.60%52.60%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters52.60%52.60%52.60%52.60%
Public47.40%47.40%47.40%47.40%

Charges & borrowings

Open charges
₹74.08 Cr
Satisfied charges
₹179.36 Cr
Breakdown by lending institutions
Yes Bank Limited₹48.15 Cr
Hdfc Bank Limited₹13.74 Cr
Others₹12.19 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
30 Sep 2026101409854Yes Bank Limited₹48.15 CrOpen
21 Sep 2026101408689Hdfc Bank Limited₹22.4 LakhOpen
14 Jul 2026101346700Hdfc Bank Limited₹12 CrOpen
04 May 2026101298868Hdfc Bank Limited₹24.28 LakhOpen
24 Dec 2025101214075Hdfc Bank Limited₹1.28 CrOpen

To see the full charge records of Brooks Laboratories Limited, buy the company report.

Total charge records: 28 View all charges

Deals & funding

Brooks Laboratories Limited has 58 deals on record (55 market trades, 1 funding round, 1 rights issue), with disclosed funding of ₹11.58 Cr; the latest was in May 2026.

Total deals
58
Market trades
55
Funding round
1
Rights issue
1
IPO
1
Disclosed funding
₹11.58 Cr

Deals on record (5 of 58)

WhenDealAmountParties
Nov 2024Market trade₹5.46 CrBuyer: One-Up Financial Consultants Pvt Ltd
Seller: an individual
May 2024Market trade₹1.28 CrSeller: Saravana Global Holdings Limited
Apr 2018Market trade₹1.46 CrBuyer: Deepthink Ventures Private Limited
Seller: Deepthink Ventures Private Limited
Sep 2016Market trade₹3.35 CrBuyer: Shrujay Trading Private Limited , 2 individuals
Seller: Shrujay Trading Private Limited , 2 individuals
Mar 2016Market trade₹1.83 CrBuyer: KL Enterprises LLP
Seller: Mudra Securities

To see the full deal history of Brooks Laboratories Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Brooks Laboratories Limited was last rated by Care on 06 Jan 2022.

Rating agencyRated onRating
Care06 Jan 2022

To see the full credit ratings and regulatory alerts of Brooks Laboratories Limited, buy the company report.

MSME payment delays

Brooks Laboratories Limited has 12 MSME Form 1 returns on record between 2019 and 2024, listing 699 overdue payments to 238 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 238)

SupplierAmount dueDue sinceReported on
Micromeg Enterprises Private Limited
an individual supplier
Shamshree Lifesciences Limited
Mac-Chem Products (India) Private Limited
Maruti Industries

To see the full MSME payment records of Brooks Laboratories Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Brooks Laboratories has 1 joint venture and 1 associated company. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.

1
Joint ventures
1
Associated companies

Employees & EPFO

Brooks Laboratories Limited has a workforce of 304 employees on its EPFO records as of May 2026, across 1 active EPFO establishment.

Employee count
304
Active EPFO establishments
1
Employee growth
3.4%

Headcount by financial year

Financial yearEmployees (EPFO)
FY 2026-27304
FY 2025-26
FY 2024-25
FY 2023-24
FY 2022-23
FY 2021-22
FY 2020-21
FY 2019-20
FY 2018-19
FY 2017-18
FY 2016-17

To see the full employee and EPFO history of Brooks Laboratories Limited, buy the company report.

GST

Brooks Laboratories has 7 GST registrations: 5 active and 2 cancelled or inactive. The first 4 active GSTINs are listed below.

Total GSTINs
7
Active
5
Cancelled / inactive
2
GSTINStateStatusRegistered on
02AACCB5316P1ZRHimachal PradeshActive01 Jul 2017
24AACCB5316P1ZLGujaratActive01 Jul 2017
19AACCB5316P1ZCWest BengalActive26 Aug 2017
27AACCB5316P2ZEMaharashtraActive19 Mar 2021

To see the full GST registrations and return filing status of Brooks Laboratories Limited, buy the company report.

Recent activity

Brooks Laboratories Limited has 42 board changes on record since 2002: 24 appointments and 18 cessations. The latest: Sonia Gupta ceased to be Director on 29 Sep 2024.

Charges
A charge with Yes Bank Limited amounted to Rs. 48.15 Cr with Charge ID 101409854 was registered on 30 Sep 2026.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.22 Cr with Charge ID 101408689 was registered on 21 Sep 2026.
AGM
Brooks Laboratories Limited last Annual general meeting of members was held on 03 Sep 2026 as per latest MCA records.
Charges
A charge with Hdfc Bank Limited of Rs. 12.00 Cr registered on 14 Jul 2026 with Charge ID 101346700 was modified on 31 Jul 2026.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 12.00 Cr with Charge ID 101346700 was registered on 14 Jul 2026.
Charges
A charge registered on 19 Dec 2024 via Charge ID 101043257 with Others was fully satisfied on 13 Jul 2026.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.24 Cr with Charge ID 101298868 was registered on 04 May 2026.
Filing
Brooks Laboratories Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Himachal Pradesh.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 1.28 Cr with Charge ID 101214075 was registered on 24 Dec 2025.
Charges
A charge registered on 25 Mar 2021 via Charge ID 100444147 with Indian Bank was fully satisfied on 31 Dec 2024.
Charges
A charge with Others amounted to Rs. 63.62 Cr with Charge ID 101043257 was registered on 19 Dec 2024.
Ceased
Sonia Gupta ceased to be Director.

90 earlier events are in the company report.

Frequently asked questions

Brooks Laboratories is an active public limited company based in Nalagarh, Himachal Pradesh, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 23 January 2002 (24+ years old) and is registered under CIN L24232HP2002PLC000267. Listed on BSE: 533543 and NSE: BROOKS.

Brooks Laboratories reported revenue of ₹85.74 Cr for FY 2025-26 (up 3.9% YoY) based on consolidated financials.

Brooks Laboratories has 6 current directors:

The latest financial statements of Brooks Laboratories on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 03 September 2026. Year-wise statements from 2015 are in the company report.

The GSTIN of Brooks Laboratories is 02AACCB5316P1ZR, registered in Himachal Pradesh. The company has 7 GST registrations in all, of which 5 are active and 2 are cancelled or inactive. Other active GSTINs include 24AACCB5316P1ZL (Gujarat), 19AACCB5316P1ZC (West Bengal), 27AACCB5316P2ZE (Maharashtra).

The CIN (Corporate Identification Number) of Brooks Laboratories is L24232HP2002PLC000267. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Brooks Laboratories is a listed company as per MCA records. Its shares are listed on both BSE (code: 533543) and NSE (symbol: BROOKS).

Brooks Laboratories has 22 court cases on record: 10 filed by the company and 12 filed against it. 4 are pending. Most are in the district courts.

Brooks Laboratories was incorporated on 23 January 2002, making it 24+ years old. It is registered with the Registrar of Companies, Himachal Pradesh.

Brooks Laboratories has 58 deals on record (55 market trades, 1 funding round, 1 rights issue), with disclosed funding of ₹11.58 Cr; the latest was in May 2026.

Sonia Gupta ceased to be Director on 29 Sep 2024. Manav Mahajan was appointed as Director on 28 Sep 2024. Deepak Mahajan ceased to be Director on 07 Aug 2024. Brooks Laboratories has 42 board changes on record in total.